Patient With CLL May Have Had Longer COVID-19 Incubation Period
Compromised immune status could have effects on disease.
Chronic Lymphocytic Leukemia News
CHRONIC LYMPHOCYTIC LEUKEMIA ADVISOR
Chronic Lymphocytic Leukemia News
Chronic Lymphocytic Leukemia Treatment Decision Making With Venetoclax-Based Therapy
A review of case studies that outline treatment decisions based on patient and disease characteristics.
Not Developing Any New Drugs Could Be EQRx’s Biggest Innovation
The best bet for a new company hoping to deliver on a lofty promise to “remake medicine” could rely on drug repurposing.
Glyphosate Exposure and Relative Risks of Non-Hodgkin Lymphoma or Multiple Myeloma
Researchers conducted a meta-analysis of 7 studies involving NHL and 3 focused on MM to determine the role of occupational exposure to glyphosate in terms of risk.
Large Consortium Study Reveals More Details on the Link Between Viruses and Cancer
Researchers use whole-genome and whole-transcriptome sequencing data to reveal viral sequences in cancer tissue.
Evidence for Increased DNA Methylation Heterogeneity in Certain Circulating CLL Cells
In this study, epigenetic heterogeneity was not associated with the birth rate of leukemic cells.
“Medical Distancing” May Help Protect Cancer Patients From Exposure to COVID-19
Screening patients by phone before they come to a clinic may help to eliminate potentially redundant visits and lower the risk of infection.
Federal Ruling Puts Pressure on Clinical Trial Sponsors to Post Data
A federal ruling will force trial sponsors to post basic results on ClinicalTrials.gov, but it is unclear whether this is a feasible mandate.
An Early Look at When CAR-T Therapy Fails Patients With CLL
A study showed how long patients with CLL may live after CAR-T therapy failure, providing a benchmark for trials evaluating therapies in the post–CAR-T setting.
First Human Clinical Trial in US to Test the Use of CRISPR-Modified T Cells in Cancer Answers Vital Questions
CRISPR-modified T cells were used in 3 patients with advanced cancer for the first time, showing modest results on tumor growth.
Improving Cancer Pain Management Amid the Opioid Crisis
Research into opioid alternatives for cancer-related pain has stalled, however substance use disorders remain problematic.
A New Trend in Drug Development: Leveraging Data from Expanded Access
Drug companies are gathering and including expanded access data in drug submissions as real-world data, but the purpose of expanded access was never for the purpose of research.
Peripheral Blood MRD Shows Promise for Assessing CLL in Patients Treated With Venetoclax
Peripheral blood sample MRD assessment will likely come into routine clinical use in the next few years, according to an expert who specializes in CLL.
Resequencing Gene Panels May Improve Prognostic Measurements for Chronic Lymphocytic Leukemia
Researchers found that mutated EGR2 and TP53 were significantly associated with worse progression-free survival in patients with chronic lymphocytic leukemia.
Second Hematologic Malignancy Deemed a “Rare” Event in CLL
The development of a second hematologic malignancy after being diagnosed with chronic lymphocytic leukemia (CLL) appears to be uncommon, a retrospective study found.
Richter Transformation Survival in CLL Appears Better Among Treatment-Naive
Continued investigation of Richter transformation may be warranted as new CLL treatments emerge.
The Questionable Practice That Permeates Oncology Clinical Trials
Most oncology phase 1 trials use a simplistic, outdated dose-finding technique, and experts agree that change is needed.
Integrative Oncology: Using Evidence-Informed Medicine to Improve Patient Outcomes and Quality of Life
Lifestyle-based integrative treatment approaches — deemed scientifically sound by the field’s proponents — merge conventional and complementary treatments.
Venetoclax and Obinutuzumab May Benefit CLL Patients With Complex Karyotype
Patients with CLL who have complex karyotype appear to have better clinical outcomes with venetoclax and obinutuzumab compared with chlorambucil and obinutuzumab.
Machine Learning Identifies Newly Diagnosed CLL Patients at Risk for Certain Outcomes
Machine learning may help identify newly diagnosed patients with CLL who are at risk for infection or treatment within 2 years of a diagnosis.
Want to read more?
Please login or register first to view this content.
Next post in Chronic Lymphocytic Leukemia
